XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
   Pharmacotherapy
   Radiotherapy
   Vaccination
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Therapy Channel
subscribe to Therapy newsletter

Latest Research : Cancer : Therapy

   DISCUSS   |   EMAIL   |   PRINT
Possibility of Separating Anticancer Properties of Vitamin D Revealed
Mar 19, 2006, 20:49, Reviewed by: Dr. Priya Saxena

�We found that we might be able to separate the two functions at the molecular level, and this raises the possibility that vitamin D can be chemically modified into a drug that will only have anticancer effects,�

 
At the right dose, vitamin D is important for bone development and may help protect against the development of several cancers, particularly colorectal cancer. However, large quantities designed to exploit the vitamin�s anticancer properties can lead to a toxic overdose of calcium in the blood. Now, research done at Georgetown University�s Lombardi Comprehensive Cancer Center indicates that it may be possible to separate the anticancer properties of vitamin D from its other functions.

Their study, reported in the journal Molecular Cell, found that mutant forms of the protein that binds to vitamin D in the cell do not allow vitamin D to promote bone development and calcium transport but do permit it to regulate an oncogenic protein known as beta catenin. Some modified forms of vitamin D itself, which do not alter bone and calcium, were also found to regulate beta-catenin.

�We found that we might be able to separate the two functions at the molecular level, and this raises the possibility that vitamin D can be chemically modified into a drug that will only have anticancer effects,� said Professor Stephen Byers, Ph.D. He and Salimuddin Shah, Ph.D., led an international group of investigators in this study.

The human body produces a lot of vitamin D from a brief exposure of the sun. The vitamin is made in the skin when a cholesterol-like molecule interacts with ultraviolet light. It has long been known that a lack of vitamin D can lead to the bone deformities associated with rickets, and the vitamin helps maintain calcium and phosphorous levels in bone and blood. Too much vitamin D, however, can spill calcium into the blood and lead to heart disease and death.

Population studies have also uncovered an interesting fact � that the risk of developing colon cancer is lower in people who live in sunny climates. Epidemiology studies have indicated that vitamin D is responsible for the protective effect of sunlight exposure on the incidence of several other cancers besides colon, including breast and prostate.

Byers and the research team suspected that beta catenin may interact with vitamin D in some fashion because of another known fact � activation of beta catenin causes most colon cancers.

To help them understand what vitamin D is doing in the cell, the researchers studied findings by other scientists who had looked at families who develop rickets due to an inherited mutation in their vitamin D receptor. Most of these patients had both rickets and alopecia (baldness). However a small number of families had mutations in the receptor which only led to rickets. �We know beta catenin is also involved in regulation of hair growth and we wondered if these particular mutations might also allow the receptor to regulate beta catenin,� Byers said.

�We found a mutation which caused rickets but not alopecia but which still allowed beta catenin to bind to the vitamin D receptor,� he said. This suggested to the researchers that it may be possible to separate the anti-cancer role of vitamin D from its effects on bone and calcium.

If a drug mimic of vitamin D can be developed, it could prove useful in preventing some cancers at their earliest stages, but would probably not offer any therapeutic benefit for later stage cancers, Byers said. �That�s because we know that by the time colon cancer is well advanced it fails to respond to vitamin D.�
 

- Molecular Cell
 

gumc.georgetown.edu

 
Subscribe to Therapy Newsletter
E-mail Address:

 

Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through our partnership with MedStar Health). Our mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis�or �care of the whole person.� The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, and the world renowned Lombardi Comprehensive Cancer Center.

Related Therapy News

Genomic signatures to guide the use of chemotherapeutics
CDK2/FOXO1 as drug target to Prevent Tumors
Telomerase inhibitors may revolutionize cancer therapy
First ever shots of the cervical cancer vaccine administered in Queensland
Gleevec can be toxic to the heart
Anti-cancer possibilities seen for certain monoamine oxidase inhibitors
AS101 protects the testis from the effects of paclitaxel
Microbeam Radiation Therapy (MRT) Could Improve Cancer Treatment
Novel EGFR antibody mAb 806 targets tumors but not normal tissues
Oral chemotherapy option soon for cancer


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us